CEDAC FINAL RECOMMENDATION on RECONSIDERATION and
REASONS for RECOMMENDATION

ELETRIPTAN HYDROBROMIDE
(Relpx—Pfizer Canada Inc.)

Description:
Eletriptan is a selective 5HT1B/1D receptor agonist indicated for the acute treatment of migraine with or without aura in adults. The maximum allowable daily dose of eletriptan is 40 mg. It is the sixth triptan to be marketed in Canada to date.

Recommendation:
CEDAC recommends that eletriptan not be listed.

Reasons for Recommendation:
1. Eleven randomized controlled trials of short duration compare eletriptan to either placebo or another triptan. Studies comparing eletriptan to placebo show that it is more effective in relieving migraine symptoms. Studies comparing eletriptan to other triptans show that it is either equivalent to or better than these triptans for some but not all migraine relief outcomes. The only meta-analysis that includes an unpublished randomized controlled trial found similar efficacy for eletriptan and sumatriptan.

2. Eletriptan, unlike other triptans, is primarily metabolized by cytochrome P-450 enzyme CYP3A4. Drugs that inhibit this enzyme raise plasma levels of eletriptan and may increase the risk of serious adverse events, including chest symptoms and coronary artery vasoconstriction. For this reason, Health Canada has limited the maximum daily dose to 40 mg. The use of eletriptan within 3 days of a potent CYP3A4 inhibitor is contraindicated.

3. Eletriptan has not been clearly shown to be more cost-effective than other triptans.

Of Note:
1. Both published and unpublished data were reviewed and taken into consideration in making this recommendation.